Mortality and economic costs are high in patients with severe sepsis, during the period of acute illness as well as subsequently.

SSTI in hospital is associated with significant mortality. Choice of empirical therapy is not evidence based, with significant under-treatment of severely ill patients.

Only commercially insured patients and direct medical costs were included, therefore, results may underestimate the economic burden of schizophrenia.

These observational data confirm that RLAI is an effective treatment in schizophrenia and high levels of adherence to therapy offers an opportunity for effective long-term disease management and significant sustained decreases in hospitalization.